The Short-term Effect of Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy

ABSTRACT

PURPOSE: To determine whether intravitreal bevacizumab is effective for the treatment of central serous chorioretinopathy. METHODS: We retrospectively examined 42 eyes after intravitreal bevacizumab (1.25 mg) injection for central serous chorioretinopathy. After 1 month, improvement of vision and change in sensory retinal detachment were evaluated with a fundus examination and optical coherence tomography. RESULTS: The mean duration of symptoms was 3.9+/-2.31 months. After intravitreal bevacizumab injection, mean best corrected visual acuity improved from 0.53+/-0.31 to 0.72+/-0.29 at 1 month. In addition, neurosensory retinal detachment disappeared in 32 patients (76.2%). Five patients among ten who did not show improvement of neurosensory retinal detachment underwent reinjection of bevaczumab, and three of those reinjected showed the resolution of neurosensory retinal detachment at another 1 month. No improvement was seen among the patients who did not undergo reinjection. CONCLUSIONS: Intravitreal bevacizumab injection appears to have a short-term benefit for the treatment of central serous chorioretinopathy.